Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details) $ in Thousands |
3 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2026
segment
|
Dec. 31, 2025
USD ($)
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Sep. 30, 2024
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Dec. 31, 2025
USD ($)
segment
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2023
USD ($)
|
|
| Segment Reporting [Abstract] | ||||||||||||
| Number of reportable segments | segment | 2 | 2 | ||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Number of reportable segments | segment | 2 | 2 | ||||||||||
| Net sales | $ 7,171,000 | $ 6,057,000 | $ 6,022,000 | $ 5,866,000 | $ 6,436,000 | $ 5,494,000 | $ 5,422,000 | $ 5,243,000 | $ 25,116,000 | $ 22,595,000 | $ 20,498,000 | |
| Cost of sales | 9,051,000 | 8,155,000 | 7,440,000 | |||||||||
| Research, development and engineering expenses | 1,623,000 | 1,466,000 | 1,388,000 | |||||||||
| Selling, general and administrative expenses | 8,651,000 | 7,685,000 | 7,111,000 | |||||||||
| Depreciation and amortization | 1,566,000 | 1,432,000 | 1,350,000 | |||||||||
| Amortization of intangible assets | (732,000) | (623,000) | (635,000) | |||||||||
| Segment net earnings (loss) | 4,889,000 | 3,689,000 | 3,888,000 | |||||||||
| Sale of inventory stepped up to fair value at acquisition | (173,000) | (46,000) | 0 | |||||||||
| Goodwill and other impairments | (170,000) | (977,000) | (36,000) | |||||||||
| Net earnings | $ 849,000 | $ 859,000 | $ 884,000 | $ 654,000 | $ 546,000 | $ 834,000 | $ 825,000 | $ 788,000 | 3,246,000 | 2,993,000 | 3,165,000 | |
| MedSurg and Neurotechnology | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Net sales | 13,692,000 | 11,753,000 | 10,558,000 | |||||||||
| Orthopaedics | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Net sales | 11,424,000 | 10,842,000 | 9,940,000 | |||||||||
| Operating Segments | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Net sales | 25,116,000 | 22,595,000 | 20,498,000 | |||||||||
| Cost of sales | 8,501,000 | 7,778,000 | 7,172,000 | |||||||||
| Research, development and engineering expenses | 1,505,000 | 1,360,000 | 1,241,000 | |||||||||
| Selling, general and administrative expenses | 6,909,000 | 6,162,000 | 5,733,000 | |||||||||
| Depreciation and amortization | 709,000 | 700,000 | 617,000 | |||||||||
| Amortization of intangible assets | (732,000) | (623,000) | (635,000) | |||||||||
| Segment net earnings (loss) | 7,492,000 | 6,595,000 | 5,735,000 | |||||||||
| Operating Segments | MedSurg and Neurotechnology | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Net sales | 13,692,000 | 11,753,000 | 10,558,000 | |||||||||
| Cost of sales | 5,253,000 | 4,748,000 | 4,338,000 | |||||||||
| Research, development and engineering expenses | 890,000 | 739,000 | 663,000 | |||||||||
| Selling, general and administrative expenses | 3,618,000 | 2,912,000 | 2,667,000 | |||||||||
| Depreciation and amortization | 231,000 | 211,000 | 195,000 | |||||||||
| Segment net earnings (loss) | 3,700,000 | 3,143,000 | 2,695,000 | |||||||||
| Operating Segments | Orthopaedics | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Net sales | 11,424,000 | 10,842,000 | 9,940,000 | |||||||||
| Cost of sales | 3,248,000 | 3,030,000 | 2,834,000 | |||||||||
| Research, development and engineering expenses | 615,000 | 621,000 | 578,000 | |||||||||
| Selling, general and administrative expenses | 3,291,000 | 3,250,000 | 3,066,000 | |||||||||
| Depreciation and amortization | 478,000 | 489,000 | 422,000 | |||||||||
| Segment net earnings (loss) | 3,792,000 | 3,452,000 | 3,040,000 | |||||||||
| Corporate and Other | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Depreciation and amortization | 125,000 | 109,000 | 98,000 | |||||||||
| Segment operating income | (889,000) | (880,000) | (780,000) | |||||||||
| Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment | ||||||||||||
| Segment Reporting Information [Line Items] | ||||||||||||
| Sale of inventory stepped up to fair value at acquisition | (173,000) | (46,000) | 0 | |||||||||
| Acquisition and integration-related charges | (335,000) | (108,000) | (20,000) | |||||||||
| Structural optimization and other special charges | (191,000) | (138,000) | (170,000) | |||||||||
| Medical device regulation | (38,000) | (58,000) | (96,000) | |||||||||
| Recall-related matters | (58,000) | (40,000) | (18,000) | |||||||||
| Regulatory and legal matters | (17,000) | (36,000) | (92,000) | |||||||||
| Net earnings | $ 4,889,000 | $ 3,689,000 | $ 3,888,000 | |||||||||
| X | ||||||||||
- Definition Inventory, Stepped-Up to Fair Value at Acquisition No definition available.
|
| X | ||||||||||
- Definition Medical Device Regulations Expense No definition available.
|
| X | ||||||||||
- Definition Rejuvenate / ABG II Hip Recall Charges No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for integration-related cost incurred in connection with business combination. Includes system integration and conversion costs; severance and other employee-related costs; restructuring and other post-combination costs. Excludes acquisition-related cost incurred to effect business combination; cost to issue debt or equity securities; and cost related to acquisition of asset. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|